Last reviewed · How we verify
IWK Health Centre — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Bolus Phenylephrine/Ephedrine Treatment | Bolus Phenylephrine/Ephedrine Treatment | marketed | Sympathomimetic amines / Vasopressors | Alpha-1 adrenergic receptor (phenylephrine); Alpha and beta adrenergic receptors (ephedrine) | Cardiovascular / Critical Care | |
| Phenylephrine bolus | Phenylephrine bolus | marketed | ||||
| Synera(TM) | Synera(TM) | marketed | Topical local anesthetic | Voltage-gated sodium channels | Dermatology/Pain Management |
Therapeutic area mix
- Cardiovascular / Critical Care · 1
- Dermatology/Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- American University of Beirut Medical Center · 1 shared drug class
- Brown, Theodore R., M.D., MPH · 1 shared drug class
- Eugene Y Rhee, MD · 1 shared drug class
- The University of Texas Health Science Center, Houston · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for IWK Health Centre:
- IWK Health Centre pipeline updates — RSS
- IWK Health Centre pipeline updates — Atom
- IWK Health Centre pipeline updates — JSON
Cite this brief
Drug Landscape (2026). IWK Health Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/iwk-health-centre. Accessed 2026-05-17.